“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon.
Cancer survivors who identify as lesbian, gay, bisexual, transgender, queer, or anything other than straight and cisgender experience more chronic health conditions, disabilities, and other physical and cognitive limitations than non-LGBTQ+ cancer survivors; however, the prevalence of most conditions was highest among transgender or gender non-conforming individuals, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
So far in 2024, 516 anti-queer bills have been introduced in state legislatures across the country, part of a coordinated effort where bills getting traction in one state are soon parroted by legislators in others.
Don Dizon, director of the Pelvic Malignancies Program at Lifespan Cancer Institute, head of community outreach and engagement at Legorreta Cancer Center, and director of medical oncology at Rhode Island Hospital, spoke with NFN Scout, executive director of the National LGBT Cancer Network, on Your Stories: Conquering Cancer podcast. In this episode, published June 25, […]
The American Cancer Society has published a first-of-its-kind study, “Cancer in People who Identify as Lesbian, Gay, Bisexual, Transgender, Queer or Gender-nonconforming (LGBTQ+)”.
Despite the continuing overall decline in cancer death rates—driven by reduction in tobacco use, improvements in early detection, and advances in treatment—the projected number of new diagnoses now tops 2 million for the first time, according to the American Cancer Society’s 2024 Cancer Statistics report.
More than 500 legislative proposals in 49 states are targeting trans people—predominantly youths—prompting fear among patients, healthcare providers, advocates, and legal experts that trans and gender nonconforming patients will be excluded from care.
At first glance, the United States Supreme Court’s 303 Creative LLC. v. Elenis ruling has nothing to do with health care—but, looking deeper, experts in oncology and law are sounding alarms that the decision can be used to discriminate against LGBTQ+ patients.
Community Outreach and Engagement (COE), now augmented with the Plan to Enhance Diversity (PED), is critical and central to the impact of NCI-designated cancer centers, and both are set forth as required components for the NCI Cancer Center Support Grant (CCSG).
Although there are more than 11 million LGBTQ+-identifying individuals in the U.S., this population remains “invisible in the research”—presenting a problem for cancer centers trying to better serve their catchment areas, said Zul Surani, associate director of community outreach and engagement at Cedars-Sinai Cancer.
